Advertisement
U.S. markets open in 2 hours 18 minutes
  • S&P Futures

    5,198.25
    -16.50 (-0.32%)
     
  • Dow Futures

    39,136.00
    -87.00 (-0.22%)
     
  • Nasdaq Futures

    18,161.00
    -70.50 (-0.39%)
     
  • Russell 2000 Futures

    2,042.90
    -6.90 (-0.34%)
     
  • Crude Oil

    82.55
    -0.17 (-0.21%)
     
  • Gold

    2,157.20
    -7.10 (-0.33%)
     
  • Silver

    25.12
    -0.14 (-0.57%)
     
  • EUR/USD

    1.0848
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.61
    +0.28 (+1.95%)
     
  • GBP/USD

    1.2685
    -0.0044 (-0.35%)
     
  • USD/JPY

    150.5000
    +1.4020 (+0.94%)
     
  • Bitcoin USD

    62,652.52
    -5,364.09 (-7.89%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.96
    -15.59 (-0.20%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Why Regeneron Pharmaceuticals, Inc. (REGN) Might Be a Diamond in the Rough

It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.

So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.

One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Regeneron Pharmaceuticals, Inc. REGN. This Medical - Biomedical and Geneticsindustry stock has actually seen estimates rise over the past month for the current fiscal year by about 15%. But that is not yet reflected in its price, as the stock lost 11% over the same time frame.

Regeneron Pharmaceuticals, Inc. Price and Consensus

Regeneron Pharmaceuticals, Inc. Price and Consensus | Regeneron Pharmaceuticals, Inc. Quote

You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 67.1%, which should ultimately translate into price appreciation.

And if this isn’t enough, REGN currently carries a Zacks Rank #1 (Strong Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Regeneron Pharmaceuticals. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for REGN and that now might be an interesting buying opportunity.

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement